Darling Ingredients: The Recovery Is Visible

Darling Ingredients is rated Buy on a visible earnings recovery, with Q1 2026 EBITDA rising to $406.8M and gross margin expanding to 26.1%, alongside a return to profitability. The core Feed and Food Ingredients segments drove the improvement, while DGD's Q1 benefit was partly boosted by a non-recurring inventory gain. The article argues the worst period is likely over and the stock screens attractively on forward valuation versus peers.

Analysis

DAR’s setup is more interesting as a margin-normalization story than a simple earnings rebound. When a processor shows EBITDA recovery without needing much top-line volume growth, the signal is that input-cost pass-through and mix are doing the heavy lifting; that typically has a faster and more durable P&L impact than demand-led growth. The second-order winner is likely the company’s own equity multiple: the market tends to re-rate these names once it believes trough margins are behind them, especially when peers are still being valued on depressed mid-cycle earnings.

The key competitive implication is that weaker processors and higher-cost collection networks should feel pressure first, not later. If DAR is extracting more value from the same feedstock pool, smaller players without scale or better hedging should lose spread, and that can force industry consolidation or at least a more disciplined procurement environment over the next few quarters. The non-obvious read-through is to renewable diesel and animal byproduct-linked supply chains: any “inventory benefit” at one segment can mask how fragile near-term earnings are if commodity relationships normalize.

The risk is that this is a margin-recovery trade, not a clean demand acceleration trade. That means the stock can keep working for months if margins stay elevated, but the setup breaks quickly if feedstock costs re-inflate, product pricing lags, or the one-time benefit unwinds into the next quarter. The market may be underestimating how much of the near-term upside is already in the tape after a sharp move in sentiment, so the real question is whether the next two prints confirm structural improvement or just confirm a cyclical bounce.

Consensus likely sees DAR as cheap because trailing earnings are depressed; the deeper point is that cheap names with visible inflections often stay cheap until investors trust the durability of the bridge from trough to normal. If the next quarter shows margin retention rather than just earnings mean reversion, the rerating can be abrupt. If not, this becomes a classic value trap masked by a single strong quarter.

Key Decisions for Investors

• Long DAR into the next earnings cycle, but size it as a 2-3 quarter catalyst trade rather than a multi-year compounder; upside is in multiple expansion if margin improvement holds, downside is a quick de-rate if the rebound proves transitory.
• Pair trade: long DAR / short a weaker processor or specialty ingredients peer with less scale and lower margin visibility; the relative trade should work if the market starts rewarding balance-sheet resilience and spread capture over headline revenue growth.
• Use call spreads instead of outright equity for a 60-120 day view on DAR; the skew is favorable if the next print confirms normalized profitability, while premium paid is capped if the inventory-related boost reverses.
• Set a post-earnings stop-loss around any guidance implying gross margin mean reversion; that would likely mark the point where the market shifts from 'recovery' to 'one-quarter anomaly.'
• If the stock gaps up on the headline, wait for a 1-2 week digestion period before adding; these earnings-recovery names often retrace 5-10% after initial enthusiasm before institutions re-enter on proof, not promise.